देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
ALENDRONIC ACID (ALENDRONATE SODIUM)
JAMP PHARMA CORPORATION
M05BA04
ALENDRONIC ACID
70MG
TABLET
ALENDRONIC ACID (ALENDRONATE SODIUM) 70MG
ORAL
15G/50G
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0150323002; AHFS:
APPROVED
2020-06-11
_JAMP Alendronate Sodium (alendronate sodium) _ _Page 1 of 42_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR JAMP ALENDRONATE SODIUM Alendronate Sodium Tablets tablet, 70 mg of alendronic acid (as sodium alendronate), Oral House Standard Bone Metabolism Regulator JAMP Pharma Corporation 1310, rue Nobel Boucherville, Québec J4B 5H3, Canada Date of Initial Authorization: June 11, 2020 Date of Revision: December 08, 2022 Submission Control Number: 265518 _JAMP Alendronate Sodium (alendronate sodium) _ _Page 2 of 42_ _ _ RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 5 4.4 Administration .......................................................................................................... 5 4.5 Missed Dose ............................................................................................................. 5 5 OVERDOSAGE ........ पूरा दस्तावेज़ पढ़ें